Drug: bevacizumab Quarter: 2016Q3
Total Records: 786 Number of Pages: 40
| DRUGNAME | PT | EventCount |
|---|---|---|
| Bevacizumab | Malnutrition | 2 |
| Bevacizumab | Mental status changes | 2 |
| BEVACIZUMAB | Metabolic disorder | 2 |
| Bevacizumab | Metastases to central nervous system | 2 |
| Bevacizumab | Metastases to lung | 2 |
| Bevacizumab | Monoparesis | 2 |
| Bevacizumab | Multimorbidity | 2 |
| Bevacizumab | Muscle haemorrhage | 2 |
| Bevacizumab | Muscle spasms | 2 |
| BEVACIZUMAB | Muscle tightness | 2 |
| BEVACIZUMAB | Musculoskeletal discomfort | 2 |
| BEVACIZUMAB | Musculoskeletal stiffness | 2 |
| Bevacizumab | Myelodysplastic syndrome | 2 |
| Bevacizumab | Myositis | 2 |
| BEVACIZUMAB | Nasal septum perforation | 2 |
| BEVACIZUMAB | Necrotising fasciitis | 2 |
| Bevacizumab | Neoplasm malignant | 2 |
| Bevacizumab | Nervous system disorder | 2 |
| BEVACIZUMAB | Neuroectodermal neoplasm | 2 |
| Bevacizumab | Oesophageal haemorrhage | 2 |
Total Records: 786 Number of Pages: 40